17790-86-2

Upstream product

• 4530-20-5 BOC-glycine 
• 59-88-1 phenylhydrazine hydrochloride 
• 100-63-0 phenylhydrazine 
• 50903-47-4 perfluorophenyl 2-((tert-butoxycarbonyl)amino)acetate 

Downstream Products

• 14723-86-5 phenylhydrazide of glycine 
• 113806-72-7 Acetic acid 5-acetoxy-2-((S)-2-tert-butoxycarbonylamino-2-{(R)-1-[(N'-phenyl-hydrazinocarbonylmethyl)-carbamoyl]-ethylcarbamoyl}-ethyl)-phenyl ester 
• 113806-69-2 {(R)-1-[(N'-Phenyl-hydrazinocarbonylmethyl)-carbamoyl]-ethyl}-carbamic acid tert-butyl ester 
• 474317-02-7 Boc-Gly-Leu-Met-Gly-Met-Gly-NHNHPh 
• 474316-89-7 N,N'-(bis-tert-butyloxycarbonylglycyl)-L-cystine bis-phenylhydrazide 
• 77162-21-1 Boc-Gly-Leu-NHNHPh 
• 51871-42-2 (S)-2-(2-(tert-butoxycarbonylamino)acetamido)-4-methylpentanoic acid 
• 4530-20-5 BOC-glycine 

Relevant academic research and scientific papers

KINASE INHIBITOR

The present invention aims to provide a novel kinase inhibitor and the like, and a therapeutic agent for a disease, a drug discovery screening method and the like utilizing such inhibitor and the like. The compound represented by the following formula (I) and a salt thereof can inhibit plural kinases including LATS (particularly LATS2) which is the major kinase in the Hippo signal transduction pathway. In addition, diseases or tissue damage associated with failure of cellular proliferation can be treated. Therefore, the present invention is beneficial, for example, in the research field of cell functions and diseases, in which the Hippo signal transduction pathway is involved, and the like. Furthermore, it is beneficial in the medical field for the treatment of such diseases and the like. wherein each symbol is as defined in the DESCRIPTION.

ADDITIVE COMPOSITION FOR CULTURE MEDIUM, ADDITIVE COMPOUND FOR CULTURE MEDIUM, AND METHOD FOR CULTURE OF CELLS OR TISSUE USING SAME

The present invention provides a medium additive composition containing a compound represented by the following formula (I), or a salt thereof: {wherein each symbol is as defined in the DESCRIPTION.}

Identification of Novel Benzoxa-[2,1,3]-diazole Substituted Amino Acid Hydrazides as Potential Anti-Tubercular Agents

Discovery and development of new therapeutic options for the treatment of Mycobacterium tuberculosis (Mtb) infection are desperately needed to tackle the continuing global burden of this disease and the efficacy and cost limitations associated with current medicines. Herein, we report the synthesis of a series of novel benzoxa-[2,1,3]-diazole substituted amino acid hydrazides in a two-step synthesis and evaluate their inhibitory activity against Mtb and selected bacterial strains of clinical importance utilising an end point-determined REMA assay. Alongside this, their potential for undesired cytotoxicity against mammalian cells was assessed employing standard MTT assay methodologies. It has been demonstrated using modification at three sites (the hydrazine, amino acid, and the benzodiazole) it is possible to change both the antibacterial activity and cytotoxicity of these molecules whilst not affecting their microbial selectivity, making them attractive architectures for further exploitation as novel antibacterial agents.

Phenylhydrazide as an enzyme-labile protecting group in peptide synthesis

The enzymatic cleavage of amino acid phenylhydrazides with the enzyme tyrosinase (EC 1.14.18.1) offers a new, mild, and selective method for C-terminal deprotection of peptides. The advantages of the described methodology are the very mild oxidative removal of the protecting group at room temperature and pH 7, a high chemo- and regioselectivity, and the availability of the biocatalyst. Even in oxygen-saturated solution, the oxidation of sensitive methionine residues was not observed. These features make the methodology suitable for the synthesis of sensitive peptide conjugates. Mechanistic data suggest that the hydrolysis of the oxidized adducts proceeds by a free-radical mechanism.